MediPharm Labs Enters Denmark Health-related Cannabis Market place, Secures New White-Label Provide Shoppers

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a international leader in specialized, analysis-driven pharmaceutical-high-quality cannabis extraction, distillation and derivative goods, right now announced it will provide cannabis concentrate goods in Denmark to two new healthcare cannabis prospects beneath two separate white-label agreements. These prospects will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ initially provide agreements for the export of completed goods to Denmark.

Denmark granted sufferers legal access to cannabis-primarily based medicinal goods two years ago as component of a 4-year pilot plan. The plan offers sufferers with protected solution access and national overall health authorities with patient information that they can use to realize usage and efficacy. According to details complied by New Frontier Information and the Danish Ministry of Overall health, more than two,one hundred sufferers (mostly ladies among the ages of 42-64) received cannabis-primarily based medicinal goods from 429 prescribing physicians beneath this plan in 2019.

“The express objective of establishing a multi-jurisdictional, GMP-certified production capability is to lead the international cannabis market place for medicinal, wellness and adult use applications and these agreements represent a further step forward in realizing our ambitions,” stated Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish healthcare market place with new and revolutionary healthcare cannabis focused goods positions us for further development in Europe and adds to MediPharm Labs all-significant physique of know-how that we are leveraging to improve the style of our formulations for sufferers and buyers everywhere.”

Beneath the agreements, a single which has an initial two-year term and the second a a single-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil goods that will be white-labeled for distribution.

MediPharm Labs anticipates delivery to its prospects to start in October 2020, pending regulatory approval by applicable overall health authorities.

GMP Certification Ignites Development for MediPharm Labs Australia

“Since the starting of 2020, MediPharm Labs Australia has secured quite a few extremely desirable domestic and international provide agreements with higher high-quality partners, now such as new prospects in Denmark,” stated Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new organization wins are a clear and significant validation of our selection to create a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs increasing profile and reputation. We appear forward to ramping up production beneath all of these agreements.”

MediPharm Labs Australia received its Great Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in Might 2020, which enables it to sell cannabis APIs and completed goods to nations across the EU, such as Denmark. The Corporation entered into its initially European white-label cannabis provide agreement that very same month with Therismos Restricted.

About Denmark’s Health-related Cannabis Market place

Denmark launched its 4-year healthcare cannabis pilot plan on January 1st, 20181. Post-harvest Great Manufacturing Processes (GMP) is expected for distribution of healthcare cannabis goods in Denmarktwo.

By means of the plan, physicians can prescribe healthcare cannabis for all purposes and are guided by suggestions in 4 locations: discomfort triggered by several sclerosis, discomfort triggered by spinal cord harm, side effects from chemotherapy remedy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The suggestions published by the Danish Medicines Agency are primarily based on an substantial evaluation of literature as effectively as assessments of: cannabis schemes in the Netherlands, Canada and Israel earlier cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high-quality cannabis oil and concentrates and sophisticated derivative goods using a Great Manufacturing Practices certified facility with ISO common constructed clean rooms. MediPharm Labs has invested in an specialist, analysis-driven group, state-of-the-art technologies, downstream purification methodologies and objective-constructed facilities with 5 major extraction lines for delivery of pure, trusted and precision -dosed cannabis goods for its prospects. By means of its wholesale and white label platforms, they formulate, customer-test, approach, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based goods to domestic and international markets. As a international leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.

For additional details, please make contact with:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 1525
E-mail: [email protected]
Internet site: www.medipharmlabs.com

______________________________
1 Medicinal Cannabis Pilot Plan. Retrieved: https://laegemiddelstyrelsen.dk/en/particular/medicinal-cannabis/citizens/medicinal-cannabis-pilot-programme/
two The Health-related Cannabis Market place in Denmark &amp Europe. Retrieved: https://www.openaccessgovernment.org/the-healthcare-cannabis-market place-in-denmark-europe/80721/
three The Danish Health-related Cannabis Pilot Programme: Placing the Patient 1st. Retrieved: https://www.healtheuropa.eu/the-danish-healthcare-cannabis-pilot-programme-placing-the-patient-initially/92991/

CAUTIONARY NOTE Concerning FORWARD-Hunting Details:

This news release consists of “forward-hunting information” and “forward-hunting statements” (collectively, “forward-hunting statements”) inside the which means of the applicable Canadian securities legislation. All statements, other than statements of historical reality, are forward-hunting statements and are primarily based on expectations, estimates and projections as at the date of this news release. Any statement that requires discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or overall performance (frequently but not constantly utilizing phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that specific actions, events or outcomes “may” or “could”, “would”, “might” or “will” be taken to happen or be accomplished) are not statements of historical reality and could be forward-hunting statements. In this news release, forward-hunting statements relate to, amongst other points, the productive overall performance of the agreements and shipping of goods thereunder as planned further development in Europe and enhancing the style of formulations. Forward-hunting statements are necessarily primarily based upon a quantity of estimates and assumptions that, even though regarded affordable, are topic to recognized and unknown dangers, uncertainties, and other elements which could lead to the actual outcomes and future events to differ materially from these expressed or implied by such forward-hunting statements. Such elements consist of, but are not restricted to: basic organization, financial, competitive, political and social uncertainties the inability of MediPharm Labs to receive sufficient financing the delay or failure to get regulatory approvals and other elements discussed in MediPharm Labs’ filings, readily available on the SEDAR site at www.sedar.com. There can be no assurance that such statements will prove to be precise, as actual outcomes and future events could differ materially from these anticipated in such statements. Accordingly, readers should really not spot undue reliance on the forward-hunting statements and details contained in this news release. Except as expected by law, MediPharm Labs assumes no obligation to update the forward-hunting statements of beliefs, opinions, projections, or other elements, should really they modify.

Latest posts